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TRIM24 in Normal and Malignant Hematopoiesis
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Treatment for acute myeloid leukemia (AML) has changed little in the past four decades.
For the majority of AML patients, current treatment options include chemotherapy and
allogeneic stem cell transplants, which also involves high-dose chemotherapy or radiation
treatment. These options have little success in the long-run, as only an estimated 26% of
patients survive five years post-diagnosis. In efforts to address this low survival rate, interest
has increased for targeting epigenetic pathways in AML. This focus stems from the discovery
that AML is frequently driven by blockades on hematopoietic stem cell differentiation, which
involves a series of coordinated epigenetic changes. Given its reported roles as an epigenetic
reader, stem cell regulator, and known oncogene, we investigated TRIM24 for putative
relevance in AML. Expression data from previous studies have also suggested roles for
TRIM24 in chronic myeloid leukemia and acute lymphocytic leukemia; however, no studies to
date have reported measurements of TRIM24 in AML from an in vivo system. Here, we report
that low TRIM24 mRNA expression in human AML patients (in TCGA) correlates with poor
survival. Additionally, this association was found to be independent of gene expression
signatures of prognostic significance, such as Gentles leukemic stem cell signature.
Furthermore, loss of Trim24 in murine, MLL-AF9-driven AML worsened survival and increased
leukemic stem cell numbers, while having no observed effects on normal hematopoiesis. These
results lay the groundwork for future investigations of the role of TRIM24 in AML, which has
the potential to aid development of novel therapeutic strategies.
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Introduction & Background:
Hematopoiesis – an overview:
Hematopoiesis is the process through which all blood cells are produced. In humans and
other mammals, this process takes place primarily within the bone marrow beginning as early as
embryonic day 15 in mice (1), and month 4 in humans (2). The hematopoietic system’s primary
responsibilities are conferring immunity and implementing transportation within an organism,
being the primary entity responsible for the transportation of nutrients, oxygen, hormones, waste
products, and immune cells. The broad range of functions required of this system are carried out
by an array of highly specialized hematopoietic cell types, each differing vastly in morphology
and function. Moreover, the constant use of these cell populations leads to a high turnover rate
of hematopoietic cells, and thus bestows an immense demand for cell production on the
hematopoietic
producing

system,

roughly

Figure 1: Overview of the hematopoietic hierarchy
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renewal (i.e. differentiation cascade), originating from a small group of stem and progenitor cells
in the bone marrow.
This hierarchy is headed by hematopoietic stem cells (HSCs), morphologically indistinct,
immature quiescent cells which have the greatest capacity for self-renewal and the slowest rate of
division within the hierarchy. HSCs comprise approximately 1 in 108 nucleated marrow cells
(non-red blood cells) in human bone marrow (3), dividing once approximately every 40 weeks
(4). Categorically, these HSCs are further sub-divided into long-term (LT) and short term (ST)
HSCs, with ST-HSCs displaying increased rates of division, and LT-HSCs possessing heightened
quiescence and self-renewal capability (5, 6). This dichotomy among HSCs adds an additional
layer to the hierarchy, thus further diluting the burden of replicative stress on the bone marrow.
These HSCs can divide both symmetrically or asymmetrically to yield multipotent progenitor
cells (MPPs) (5, 6). MPPs have a lower capacity for self-renewal compared to HSCs, but,
conversely, have a higher rate of division (5-7). As the name implies, MPPs are capable of further
differentiating into multiple more specialized progenitor cells, and are more directly responsible
for meeting the cellular demands imposed on the bone marrow. MPPs differentiate into one of
many lineage-committed progenitors, which subsequently divide and differentiate into the mature
effector cells of the hematopoietic system, such as erythrocytes, platelets, granulocytes,
macrophages, T-cells, B-cells, and NK cells. Granulocytes and macrophages are derived from
common myeloid progenitors (CMPs), erythrocytes and platelets are derived from
megakaryocyte-erythrocyte progenitors (MEPs) (which themselves can be derived from CMPs or
MPPs), and T-cells, natural killer cells, and B-cells are derived from common lymphoid
progenitors (CLPs). This extensive hierarchy of self-renewal and differentiation provides an
elegant system in which all the hematopoietic cell types required by an organism can be produced
while minimizing divisions within the HSC pool. While recent evidence suggests this hierarchical
2

system may not be as rigid as previously thought (8-10), this model effectively captures the
general strategy through which a single human HSC division can lead to the production of over 1
x 107 hematopoietic cells (4, 11).
The HSC is the centerpiece of the hematopoietic system, being crucial for maintaining the
fidelity of all hematopoiesis. As such, the self-renewal, proliferation, and differentiation of HSCs
are each governed by a multitude of epigenetic and extracellular mechanisms, all of which
coordinate together as part of the hematopoietic stem cell niche. More specifically, the HSC niche
is the culmination of physical and biochemical cues from surrounding adipocytes, nerve cells,
osteoclasts, osteoblasts, endothelial cells, mesenchymal cells, blood vessels, and sinusoids in the
bone marrow. This specialized microenvironment enforces tight regulations on all HSC activities,
and is partly responsible for preventing malignant expansion of the stem cell pool (12, 13).
Hematopoietic malignancy:
The hematopoietic system is inherently prone to malignancies, as the demand for cell
production on the hematopoietic system is high in comparison to other tissues (14-17). The
hematopoietic system has evolved specific mechanisms to counter this replicative stress, the most
notable of which are the aforementioned hierarchy and niche. Additional mechanisms, such as
regulation by P53 and common apoptotic pathways, help to further counteract effects of the
immense replicative stress intrinsic to the bone marrow (18-20). In spite of these mechanisms,
an estimated 173,000 hematopoietic cancers were diagnosed in 2017 within the United States, in
addition to 10,000 – 20,000 neoplasms and proliferative disorders such as myelodysplastic
syndrome (MDS) (21). Roughly one-third of these cases were leukemia, with 60,000 new cases
of leukemia diagnosed in the United States each year and a corresponding 24,000 deaths,
accounting for roughly 4% of all new cancer cases and deaths (21). Roughly 380,000 people are
3

living with leukemia at any time in the US, with an average 5-year survival rate just over 60%
(21).
Depending on the maturation level of malignant cells, leukemias are generally classified
as chronic or acute, with acute leukemia having a more severe blockade on cell differentiation,
and thus a more profound impediment on hematopoietic cell function and patient survival time
(21). Both chronic and acute leukemias are further categorized by the cell types the malignancies
most closely resemble, and are thought to partly reflect the cell type from which the malignancy
originated (22-24). The most common types are lymphocytic and myeloid, but mixed lineage
leukemias are also observed (25-28). Among these, Acute Myeloid Leukemia (AML) patients
have an unfavorable prognosis, with a 5-year survival rate of only 26% (21). These also constitute
roughly a third of all leukemia patients, with approximately 21,000 new cases and 10,500 fatalities
annually (21). Acute Myeloid Leukemia (AML), as the name indicates, is an acute leukemia in
which cells display a myeloid phenotype. AML is also frequently described as a malignancy of
the HSC niche, being that this hematological malignancy originates almost exclusively from
hematopoietic stem and progenitor cells (HSPCs) within the bone marrow (29-31). Malignant
transformation of HSPCs gives rise to leukemic initiating cells (LICs), a completely self-renewing
population of leukemic cells largely agreed to be responsible for driving progression of the disease
(29-31). AML can be further sub-divided by utilizing the French-American-British (FAB)
classification system for AML, which classifies AML cases based on the cell type the malignant
cells most closely resemble (26). In this system, the subtypes M0 – M7 correspond with levels
of cellular maturation, with M0 patients displaying the least differentiated cells, and M4-M7
patients displaying more mature cell types (26). This classification system is still broadly used,
but in recent years has been more frequently used in conjunction with molecular markers, such as
point mutations and chromosomal abnormalities (32).
4

While 5-year survival for all leukemias has nearly quadrupled since 1960, AML 5-year
survival rates hover at approximately 26%, as most drugs have proven to be ineffective in the
long-term (21, 33, 34). The exception is all-trans retinoic acid (ATRA), approved by the FDA in
1995 to treat the M3 FAB subtype of AML (34-36). This subtype of AML, also known as acute
promyeloitic leukemia (APL), frequently harbors a translocation which results in the expression
of a PML-RARα fusion protein, halting differentiation in the promyeloitic stage. The APL
treatment ATRA operates on a concept known as differentiation therapy, which works by forcing
the self-renewing, immature populations of malignancies to terminally differentiate, hence
ablating their ability to sustain long-term proliferation and disease. Specifically for APL, this
terminal-differentiation is induced by disrupting signaling from the PML-RARα fusion protein,
thus removing the underlying cause for the differentiation blockade (36). While the role of ATRA
is currently limited to the M3 subtype of AML, this treatment is an exemplar for demonstrating
the feasibility of differentiation therapies, potentially serving as an archetype for future
treatments. As such, exploiting differentiation pathways among hematopoietic cells or targeting
pathways necessary for maintaining pluripotency have become key areas of interest for leukemia
research.
Epigenetics in Acute Myeloid Leukemia:
In accordance with its relevance for the future of differentiation therapy, epigenetics plays
a central role for the development of acute myeloid leukemia. This is largely evident from patient
sequencing data obtained within the past decade, revealing that over 40% of patients do not have
an identifiable mutation in a signaling gene (such as KRAS or NRAS), and that over 70% of
patients have at least one non-synonymous mutation in an epigenetic modifier (37). Moreover,
these mutations have been frequently identified in genes with global epigenetic influence on the
genome, such as DNMT3A and TET2 (37). This information, together with gene expression and
5

amplification data obtained from childhood and adult AML cases, has demonstrated that
aberrant epigenetic signatures are a universal theme in human leukemia (37, 38).

This

prevalence supports the notion that epigenetic dysregulation is paramount for the initiation or
maintenance of hematopoietic malignancies. The pervasive involvement of epigenetics in AML
is perhaps best understood when interpreted in the context of what is currently known about
normal hematopoiesis. The transition from HSC to mature effector cell is a series of coordinated
epigenetic changes. As such, any alteration in an epigenetic pathway could lead to a failed step
in the differentiation hierarchy. Any such block on differentiation has the potential to result in
the eventual development of a hematopoietic malignancy, such as AML. These observations and
rationale have recently demonstrated utilitarian value in the clinic, as methylation profiling has
been used to classify subtypes of AML with prognostic significance (39-42).

Similarly,

methylation profiling has been used to predict the stemness of patients’ AML, with stemness itself
being negatively associated with survival, and highly informative about a patient’s progression
and response to treatment (43, 44). However, this significance appears to not solely be limited to
epigenetic modifiers. An increasing amount of evidence suggests that epigenetic readers, proteins
which interact with epigenetic modifications to enact changes in gene expression or chromatin
organization, also play a role in leukemic progression (45, 46). This knowledge extends putative
relevance in AML to any gene participating in epigenetic pathways, be it through enzymatic or
merely associative means.
Fusion genes in Acute Myeloid Leukemia:
The importance of epigenetics in leukemia was first recognized through the study of
chromosomal abnormalities in patients, as clinical observations revealed that recurring
translocations in leukemia patients produced fusion proteins frequently involving at least one
epigenetic modifier, such as MLL, MOZ, CBP, P300, or NSD1 (37).
6

Such chromosomal

translocations are common in AML, being present in 30% of non-complex karyotype patients
(47).

Prognoses vary substantially across patients with each fusion-protein, with patients

harboring MLL-fusion proteins among the poorest (48-50). In genetically normal cells, the MLL
gene (KMT2A) produces an H3K4 methyltransferase tasked with maintaining appropriate
expression of the HOXA cluster, a collection of genes which positively regulates self-renewal and
stemness in hematopoietic stem and progenitor cells (HSPCs). Upon forming a fusion protein,
the MLL complex co-localizes (by virtue of its nature) with its fusion partner to MLL-target
locations within the genome, thereby also recruiting complexes the fusion partner may associate
with. MLL-fusion leukemia is further subdivided by translocation partner, with over 80 fusion
partners being described in the literature (51). The most common fusion partners for MLL in
AML are AF9, ENL, AF10, ELL, and AF4 (51), all of which are members of the super elongation
complex (SEC), a large multi-protein complex responsible for exerting global effects on
transcription (51-54). In AML, MLL-fusion proteins alter both the recruitment and activity of
SEC and DOT1L (H3K79 methyltransferase) to enforce aberrantly high HOXA cluster expression
(52, 55). Consequently, this powerful combination of epigenetic modifications and global changes
in the transcriptional program in MLL-fusion AML patients leads to a blockade on differentiation
and malignant transformation of HSPCs.
Akin to results from ATRA treatment in M3 AML, recent evidence suggests
differentiation blockades in MLL-fusion leukemia can be circumnavigated (56); however, unlike
the direct targeting of the PML-RARa fusion in M3 AML, differentiation therapy in MLL-fusion
AML will likely be enacted through targeting other epigenetic pathways. For example, epigenetic
modifiers previously unappreciated in AML, such as protein-arginine methyltransferase 5
(PRMT5), have been demonstrated to be therapeutically relevant targets for removing the
differentiation blockade and reducing self-renewal capacity in both mouse models and human cell
7

lines (57). Such discoveries highlight the importance for searching for proteins with epigenetic
writing or reading ability, and experimentally assaying their potential relevance for MLL-fusion
AML treatments and differentiation therapies.
TRIM24 as an Epigenetic Reader and a Regulator of P53:
TRIM24 is a member of the Tripartite Motif-containing (TRIM) family, a superfamily
known for E3 ubiquitin ligase activity as well as regulation of autophagy and innate immunity
(58, 59). TRIM24 is located on the distal end of the q-arm of chromosome 7 in humans, and
produces a 1050 amino acid, 117 kDA protein (60). TRIM24 possesses an RBBCC domain
towards the N-terminus, consisting of of a RING domain, a B-box, and a coiled-coil. This domain
is followed by an LXXLL motif (NR box) starting at amino acid 754, and a PHD and Bromo
domain at the C-terminus (58-63). The RING domain of TRIM24 confers the enzymatic function
of an E3 ubiquitin ligase, and has been demonstrated to directly target p53 for proteasomal
degradation (61, 62). Furthermore, TRIM24 has also been shown to participate in a negative
regulatory feedback-loop with p53 in a manner similar to that of MDM2 (61). Meanwhile, the
PHD domain of TRIM24 has been shown to preferentially bind Histone 3 Lysine 4 in the
unmethylated state (H3K4me0), while the Bromo domain of TRIM24 has been demonstrated to
preferentially associate with Histone 3 Lysine 23 in the acetylated state (H3K23ac)(63). Via
histone peptide arrays, the simultaneous binding of both histone marks has been demonstrated to
be critical for the independent association (i.e. in the absence of other proteins) of TRIM24 with
chromatin (63).

This association has been demonstrated to only be favorable in the cis-

conformation, as other arrangements have poor binding kinetics (63). The simultaneous presence
of both of these chromatin marks represents a non-canonical histone signature, the roles of which
have yet to be fully investigated (63).
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Originally known as Transcription Intermediary Factor 1 Alpha (Tif1α), the first study on
Trim24 was published in 1995, which reported Trim24 as a component of the mouse
hepatocellular carcinoma fusion oncoprotein, T18 (64, 65). At the time of this study, TRIM24’s
known roles were limited to interactions with nuclear receptors and enhancement of retinoic acid
receptor signaling (65). While informative, TRIM24 research remained little beyond the scope of
nuclear receptor signaling until the Barton lab demonstrated its role as a p53-targeting E3
ubiquitin ligase in 2009 (66). Knowledge of TRIM24 has since expanded drastically, with
demonstrated roles in Wnt, PI3K/Akt, and STAT signaling, as well as in innate immunity,
pluripotency, and embryonic stem cell transcription (67-74). Through manipulating these
pathways, overexpression of TRIM24 has been demonstrated to influence a wide variety of human
malignancies, including breast cancer, head & neck cancer, glioblastoma, non-small-cell lung
cancer, prostate cancer, cervical cancer, and hepatocellular carcinoma (63, 70, 75-81). In the case
of hepatocellular carcinoma, both overexpression and deletion of TRIM24 lead to malignancy (78,
79). This indicates that the role for TRIM24 may not be as simple as that of a typical oncogene,
but may rather be part of a balancing act in preventing oncogenesis, requiring regulation in a
precise, context-dependent manner.

This balancing act may hold relevance for so far

uninvestigated malignancies with respect to TRIM24, the prospect of which warrants further
investigation.
Rationale – TRIM24’s Putative Role in AML:
The functional abilities of TRIM24, and the pathways they regulate, make the gene an
interesting candidate for examining its therapeutic relevance in AML. Accordingly, TRIM24 has
recently been within the focus of gene expression studies conducted on both ALL and CML
samples (82, 83). In CML, TRIM24 expression was elevated in the late stages of CML, suggesting
it may play a role in the transition to blast crisis, the most advanced form of the disease (83).
9

Conversely, in ALL, TRIM24 mRNA

Figure 2: TRIM24 mRNA correlates with human survival

expression was associated with favorable
patient status, as patients expressing higher
levels of TRIM24 mRNA displayed a lower
percentage of blast cells (undifferentiated
cells) 28 days post-diagnosis (82). In both
cases, the data suggests that TRIM24 may
affect pathways central to the malignant
hematopoietic state. As is the case with
hepatocellular carcinoma, the above data
suggests that TRIM24 may play a balancing
act in leukemia, potentially exhibiting
varied,

context-dependent

effects

on

Y-axis represents percent of surviving patients while x-axis
represents months of patient survival post-diagnosis.
TRIM24 high expressing patients (red) and TRIM24 low
expressing patients (blue) were separated into their
respective groups based on their TRIM24 expression in
comparison to the mean TRIM24 expression of the group.
All data in this figure was obtained from TCGA.

hematopoietic malignancies. If and how this may relate to Trim24 in AML has yet to be
determined. As acute leukemias generally share more similarities than they do with chronic
leukemias, TRIM24 is more likely to affect AML in a manner similar to how it affects ALL, than
CML. To this end, a review of the literature revealed that the genomic location of TRIM24
(chromosome 7q) is deleted in roughly 10% of both AML and MDS patients, and is associated
with a poor prognosis in both instances (84, 85). An additional search among data available in
The Cancer Genome Atlas (TCGA) AML dataset revealed that patients above mean TRIM24
mRNA expression survived roughly 1.8 times longer than patients below mean TRIM24 mRNA
expression (p-value 0.0003) (figure 2).
These combined data have led us to hypothesize that loss of TRIM24 promotes the
progression & aggressiveness of AML. Moreover, AML is characterized by the aberrant
10

expression of genes crucial for hematopoietic development & maintenance. This, coupled with
the demonstrated roles for TRIM24 in regulating embryonic stem cell expression & pluripotency,
has led us to also hypothesize that TRIM24 plays an important role in normal hematopoiesis.
To address these hypotheses, we aim to characterize the role of TRIM24 in acute myeloid
leukemia, and define its role in normal hematopoiesis (detailed in figure 3).
Figure 3: Aims of study
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Results:
Colony formation:

Figure 4: Trim24 knockout cells have increased
colony formation ability

In order to gauge the self-renewal
capacity of MLL-AF9 transformed leukemic
bone marrow for both Trim24 wildtype and
Trim24 knockout cells, colony formation
assays were performed in a semisolid medium
supplemented with cytokines. For passage 1,
the colony formation assays (n=3) yielded an
average of 151.7 ± 42.4 colonies for Trim24
knockout cells and 60.7 ± 20.2 colonies for

The y-axis represents total colony count per passage,
while the x-axis contains the categories for Trim24
wildtype (red), and Trim24 knockout (blue), for each
passage of cells in the experiment (3 in total).

wildtype cells. The difference between these
two groups is 91 colonies, with a p-value of

0.12. For passage 2, the Trim24 knockouts averaged 166.7 ± 46.8 colonies, and the wildtypes
averaged 66.7 ± 22.1 colonies, with a difference of 100 between the two groups and a p-value of
0.13. For passage 3, the Trim24 knockouts averaged 183.3 ± 63.5 colonies, and the wildtypes
averaged 68.6 ± 36.7 colonies, with a 114.7 difference between the two groups, and a p-value of
0.19.
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Cell counts:
In order to gauge for potential effects on

Figure 5: Trim24 knockout cells have
increased cell number in vitro

proliferation, cell counts were performed on
several passages of Trim24 wildtype and Trim24
knockout cells in semisolid media (n=3). Trim24
wildtype cells produced an average of 2.5 ± 0.5 x
106 cells per passage, whereas Trim24 knockout
cells produced an average of 3.56 ± 0.1 x 106 cells
per passage.

This yields a roughly 1.1 x 106

difference between the two groups, approaching
significance with a resulting p-value of 0.0634.

The y-axis represents total cell number per
passage. The x-axis contains the categories for
the control group (Trim24 WT), and Trim24
knockout (-/-).

Giemsa stains:
Giemsa stains aid in the visualization of

Figure 6: Trim24 knockout cells show no
difference in blast percentage

morphological differences between hematopoietic
cell types by not only making cellular features such
as the nucleus more distinct, but by also providing
unique staining patterns for specific cell types (such
as light pink stain for erythroid cells). This staining
provides the stark visual differences needed to
manually distinguish between hematopoietic cell
types, and enables manual enumeration of major
hematopoietic cell populations. As such, this is
frequently used as a method to measure blast counts
13

The y-axis represents the percentage of blast
cells out of total cells enumerated via Giemsa
staining. The x-axis represents the categories of
Trim24 knockout (blue) and Trim24 wildtype
(red) for both in vivo and in vitro experiments.

and biases towards the maturation of specific hematopoietic lineages. After performing Giemsa
stains on in vitro generated Trim24 knockout and wildtype AML, we measured no significant
difference in blast counts, with the knockout group displaying a blast percentage of 79, and the
wild-type group a percentage of 81.7, with a 0.85 p-value between the two groups. Additionally,
a similar result was observed in subsequent in vivo assays, with the knockout group displayed a
blast percentage of 26.3, and wild-type group a percentage of 31.3, with a 0.7 p-value between
the two groups.
Primary transplant:
For better understanding the potential
role Trim24 may play in in vivo survival, we

Figure 7: Mice with Trim24 knockout primary AML
trend toward survival disadvantage

injected mice with Trim24 knockout and
wildtype leukemic cells generated in vitro, in
an assay known as a primary leukemic
transplant. The primary transplant revealed
that mice with Trim24 wildtype leukemia
succumbed to the disease after an average of
49 days, whereas the mice with Trim24
knockout leukemia succumbed after an
average 70.5 days, with 50% censored at day
80.

The y-axis represents the percentage of surviving
patients in each group, while the x-axis represents the
time of survival for mice after being injected with
leukemic cells. Trim24 knokcout group is represented in
blue, whereas the Trim24 wildtype group is represented
in red.

This yields a 21.5 day difference

between the two groups, approaching statistical significance with a p-value of 0.0814. Two
repeats of the primary transplant have so far failed to engraft.
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Secondary transplant:
We next performed what is known as a
secondary

leukemic

transplant

by

harvesting leukemic bone marrow cells

Figure 8: Mice with Trim24 knockout secondary
AML show strong survival disadvantage.
a)

from deceased mice in the primary
transplant, and subsequently re-injecting
them into immunocompromised mice. The
purpose of such serial transplantations is to
reveal long-term differences in the ability
of a genotype to maintain a leukemic

b)

initiating cell (LIC) population, as such
differences in self-renewal capacity are not
always readily observable in primary
transplants.

The secondary transplants

revealed a stark difference in the survival
times between mice with Trim24 wildtype
leukemia and mice with Trim24 knockout
leukemia,

with

the

knockout

group

displaying an average survival of 30.8
days, and the wildtype group displaying an

For both figure 8 a) and figure 8 b) the y-axis represents
the percentage of surviving patients in each group, while
the x-axis represents the time of survival for mice after
being injected with leukemic cells. Trim24 knokcout
group is represented in blue, whereas the Trim24
wildtype group is represented in red. Figure 8 a)
represents the first iteration of the secondary transplant,
whereas figure 8 b) represents a repeat.

average survival of 66.8 days, with 4 out of
6 censored at day 80. This gives a 36 day difference between the survival of the two groups,
reaching statistical significance with a p-value of 0.0012. The secondary transplant was repeated,
with the knockout group displaying an average survival of 45 days, and the wildtype group
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displaying an average survival of 100 days, with 5 out of 6 censored at day 100. This gives a 55
day difference between the survival of the two groups, reaching statistical significance with a pvalue of 0.0017.
Leukemic initiating cells:
To enumerate the rare cell population within

Figure 9: Mice with Trim24 knockout AML
show 6-fold increase in leukemic initiating cells

leukemic tissue known as leukemic initiating
cells (LICs), we performed antibody-staining
and flow cytometry analysis on Trim24
knockout and wildtype leukemic bone marrow
from the transplantation experiments. The flow
analysis revealed that mice with Trim24
knockout leukemia have approximately six
times as many leukemic initiating cells (GFP +,
Sca1 -, lineage low, C-kit +, CD34 +, FcyR III/II
-), with the knockout group having an average of

The y-axis represents the total number of leukemic
initiating cells (LICs) enumerated per sample,
while the x-axis contains the categories of Trim24
wildtype leukemia (control) and Trim24 knockout
leukemia (Trim24 -/-).

approximately 870,000 leukemic initiating cells, and the wildtype group having an average of
approximately 142,000 leukemic initiating cells. The exact difference is statistically significant,
reaching a p-value of 0.0247.
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HOXA cluster expression:
To determine if altered HOXA cluster
expression, a hallmark of MLL-fusion AML,

Figure 10: Mice with Trim24 knockout AML
show no difference in HOXA cluster expression.
a)

varied between Trim24 knockout and wildtype
leukemic mice, we isolated RNA from our
leukemic tissue, and performed qPCR. Analysis
of the qPCR data revealed no significant
difference in the expression of HOXA9, with
Trim24 knockout leukemic cells expressing 0.9
the amount of wildtype cells, with a nonsignificant p-value of 0.21.

b)

Additionally no

significant difference in the expression of
MEIS1 (canonically expressed with the HOXA9
cluster) was detected either, with Trim24
knockout leukemic cells expressing 1.06-fold
more than wildtype cells, with a non-significant
p-value of 0.24.
Prognositc indicators:
To gather a more complete understanding of the

In
both figure 10 a) and figure 10 b), the y-axis
represents mRNA expression normalized to the
control group (Trim24 wildtype), while the x-axis
contains the categories “Control” and “Trim24
knockout”. Figure 10 a) contains data for
expression of HOXA9, while figure 10 b) contains
data for expression of MEIS1.

putative clinical relevance of TRIM24, we first examined TRIM24 mRNA expression in the
context of patient prognostic markers. As can be seen in (figure 11 a), based on cytogenetic
prognostic markers, TRIM24 mRNA expression correlated with a favorable prognosis, with
patients in the “Good” group expressing an average of 2784 reads per kilobase million (RPKM),
17

while patients in the “Intermediate” and “Poor”

Figure 11: TRIM24 mRNA correlates with
favorable prognostic markers, independent of
mutation rate.
a)

groups expressing an average of 1918 and 1703
RPKM of TRIM24 mRNA respectively. After
performing an ANOVA, the resulting p-value
was less than 0.0001 in both cases when
comparing “Good” to “Intermediate” or
“Poor”. No statistically significant difference
was

observed

when

comparing

the

“Intermediate” or “Poor” groups. Additionally,
b)

to determine if the observed association with a
favorable prognosis could be attributed to
altered mutation frequency, we next compared
mutation rate with TRIM24 mRNA expression
per patient. Shown in (figure 11 b), TRIM24
mRNA did not correlate with mutation rate in

In figure 11 a) the y-axis represents TRIM24
mRNA expression in reads per kilobase million
(RPKM), while the x-axis contains three prognostic
categories. In figure 11 b) the y-axis represents
TRIM24 mRNA expression in RPKM, while the xaxis represents total exome mutations per patient.
All data in both figures were obtained from TCGA.

the TCGA AML dataset. Linear regression
analysis resulted in a slope of 19.47, less than
1% of the mean TRIM24 mRNA expression,
and was not statistically significant, with a p-

value of 0.115. The R-value (correlation coefficient) of the regression line generated was 0.015.
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TRIM24 mRNA expression by AML subtype:
To assess the potential for
subtype-specific biases of TRIM24
expression,
relationship

we

examined

between

Figure 12: TRIM24 mRNA expression varies across
distinct AML subtypes

the

TRIM24

expression and FAB subtype.

As

shown in (figure 12), the M3 FAB
subtype displayed the highest mean
TRIM24 mRNA expression with an
average of 2709 RPKM, reaching
statistical

significance

when

compared to M1, M4, and M5.
Additionally,

the

M5

subtype

The y-axis represents TRIM24 mRNA expression in RPKM,
while the x-axis contains categories containing the six mostfrequent subtypes of AML, according to the French-AmericanBritish (FAB) classification system.

displayed the lowest mean TRIM24
mRNA expression with an average of 1173 RPKM, reaching statistical significance when
compared to M0, M1, M2, and M3.
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TRIM24 mRNA in HSCs & AML subtypes:
As changes between hematopoietic stem
cells (HSCs) and leukemic cells can be indicative

Figure 13: TRIM24 mRNA is reduced in AML
subtypes when compared to HSCs.

of alterations beneficial to leukemic progression,
we next examined TRIM24 expression among five
AML types and compared the mean expression of
each group to that of HSCs. The data utilized for
this analysis was obtained from the BloodSpot
database.

The BloodSpot database executes a

batch-correction protocol on microarray data from
various studies in order to make them comparable,
enabling the comparison of leukemic data from the
MILES study to hematopoietic data obtained from
individual researchers. As can be seen in (figure

The y-axis represents TRIM24 mRNA expression
in RPKM, while the x-axis contains categories of
five AML subtypes, and one category for
hematopoietic stem cells (HSC). All data in this
figure was obtained from the BloodSpot database.

13), TRIM24 expression is reduced among all five AML subtypes when compared to HSCs, all
reaching statistical significance, each with a p-value less than 0.0001.
TCGA patient survival:
To further evaluate TRIM24’s potential clinical relevance, we next examined survival
trends between patients above mean TRIM24 mRNA expression, and patients below mean
TRIM24 mRNA expression. As can be seen in (figure 14 a), patients with above mean TRIM24
mRNA expression survived an average of 35.6 months, whereas patients below mean TRIM24
mRNA expression survived an average of 19.6 months. The survival difference between these
two groups is significant, reaching a p-value of 0.0003.
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As can be seen in (figure 12),
TRIM24 expression correlated with the M3

Figure 14: TRIM24 mRNA correlates with human
survival across subtypes.
a)

FAB subtype of AML, which has a strongly
favorable prognosis in comparison to the
other FAB subtypes. To understand to what
extent this association could be affecting
the observed survival trend, we performed
a separate survival analysis excluding all
M3 patients (16 total).

The resulting
b)

analysis (figure 14 b) shows that excluding
M3 patients did not substantially affect
survival, with a resulting p-value still
significant at 0.0057. To further scrutinize
the relationship between TRIM24 mRNA
expression and survival, our bionformatics
collaborator (Yi Zhong) performed an
independent survival analysis (figure 15) by
removing arbitrary cut-offs such as “the
mean”, and instead used an optimized
cutoff to define TRIM24 high and lowexpressing groups (see methods).

This

The y-axis represents percent of surviving patients while
the x-axis represents months of patient survival postdiagnosis. TRIM24 high expressing patients (red) and
TRIM24 low expressing patients (blue) were separated into
their respective groups based on their TRIM24 expression
in comparison to the mean TRIM24 expression of the
group. All data was obtained from TCGA. Figure 14 a)
and figure 14 b) differ only in that patients of the M3
subtype (16 in total) were excluded from the analysis in
figure 14 b).

survival analysis was congruent with the prior two analyses, with TRIM24 high expressing
patients surviving longer than TRIM24 low expressing patients, with a p-value of .0007.
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Figure 15: Trim24 mRNA correlates with
survival in independent, optimized-cutoff,
ranked survival analysis.

The y-axis represents the proportion of surviving
patients in comparison to the total patients
surviving (with 100% surviving represented by 1).
The x-axis represents days survived post-diagnosis.
TRIM24 high expressing patients (red) and
TRIM24 low expressing patients (green) were
defined by an optimzed cut-off algorithm. All data
analyzed was obtained through TCGA. This figure
is the reuslt of a collaboration with Yi Zhong.
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TCGA Patient characteristics:
To determine if patient cell type biases were observed on the basis of TRIM24 expression,
we next examined TRIM24 expression per patient in the context of various patient hematopoietic
cell types. Demonstrated in (figure 16), TRIM24 expression did not reaveal any statistically
significant correlation with peripheral blood blast percentage (p-value 0.32), white blood cell
count (p-value 0.11), basophil count (p-value 0.93), abnormal lymphocyte count (p-value 0.13),
nor platet count (p-value 0.43). TRIM24 did demonstrate a stastistically significant linear
relationship with bone marrow blast percentage (p-value 0.02); however, the R-value (correlation
coefficient) obtained from the linear regression analysis was 0.033, indicating an extremely weak
linear relationship. The resulting slope (-8.3) is less than 0.41 % of the mean TRIM24 mRNA
expression.
Figure 16: TRIM24 mRNA does not correlate with enumerated patient cell types.
a)

d)

c)

b)

e)

f)

For figures 16 a) through figure 16 f), the y-axis represents TRIM24 mRNA expression in RPKM while the xaxis represents numbers of white blood cells (WBC), basophil count, bone marrow blast percentage,
abnormal lymphocyte percentage, platlet count, and peripheral blood blast percentage, respectively. All data
in this figure was obtained through TCGA. The black line in each figure represents the slope generated from
linear regression analysis.
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TCGA HOXA cluster expression:

As with our in vitro and in vivo mouse

Figure 17: TRIM24 shows only weak association
with HOXA cluster expression in TCGA.

AML samples, we next measured the co-

a)

expression between TRIM24 and HOXA9, and
TRIM24 and MEIS1 among all TCGA AML
patients with mRNA sequencing data available.
Statistically significant relationships were
observed in both instances, with p-values of
less than 0.0001; however, the associations
b)

were weak, with HOXA9 co-expression
yielding an R-value of 0.13, and MEIS1
expression an R-value of 0.09. Repeating the
analysis by examining TRIM24 mRNA rank in
comparison to HOXA9 or MEIS1 expression
rank yielded a similar result, with R-values of

In both figure 17 a) and figure 17 b) the y-axis
represents TRIM24 mRNA expression in RPKM,
while in 16 a) the x-axis represents MEIS1 expression
in RPKM, and in 16 b) the x-axis represents HOXA9
expression in RPKM. The black line in each figure
represents the slope generated from linear regression
analysis.

0.16 and 0.15 respectively.
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Pathway Enrichment:
As the major gene cluster which facilitates LIC expansion in MLL-fusion AML was not
strongly associated with TRIM24 expression, we decided to next perform gene enrichment
analysis on the co-expression data available from TCGA. Through collaboration with Yi Zhong,
we obtained over 600 pathways significantly associated with TRIM24 expression; however, many
of these pathways encompassed various pathways involved in immune cell functions. As such,
in table 1, we chose show the enrichment of 7 broad pathways which encompass many of the
other pathways enriched in the TRIM24 co-expression data. Additionally, at the bottom of table
1, we show the non-significant p-value for the association of a leukemic stem cell signature
accepted for its prognostic value. This lack of an association with the canonical leukemic stem
cell signature suggests a non-canonical survival mechanism may be responsible for TRIM24’s
associations with survival (see discussion).
Table 1: Summarized pathway enrichment analysis

The leftmost column displays the names for gene expression signatures from the Gene Ontology (GO)
database. The middle column represents the p-value associated with their enrichment based on TRIM24
mRNA expression, while the rightmost column displays nature of the association (i.e. positive vs.
negative correlation). The first seven pathways listed represent pathways of interest for their statisticallysignificant associations with TRIM24 mRNA, whereas the eighth pathway listed is a pathways with
prognostic significance, noted in the literature for its association with leukemic stem cells.
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Each of the pathways in
Table 1 were evaluated for its

Figure 18: Leukoctye activation signature negatively
correlates with human survival.

correlation with survival in TCGA
AML patients.
leukocyte

Among these,

activation

strongly

associated with survival with a pvalue of 0.0067 when comparing
patients above and below median
expression for the signature (figure
18).
To determine if TRIM24’s
negative association with the more
mature M4 and M5 FAB subtypes
(seen in figure 12) could account for
TRIM24’s negative association with

The y-axis represents percent of surviving patients while the xaxis represents days of patient survival post-diagnosis.
Leukocyte activation high-expressing patients (red) and
leukocyte activation low-expressing patients (blue) were
separated into their respective groups based on their TRIM24
expression in comparison to the median leukocyte activation
expression of the group. All data in this figure was obtained
from TCGA, and analyzed through software available through
the BloodSpot database.

the leukocyte activation signature,
we measured the co-expression of TRIM24 with the “leukocyte activation” signature among solely
M4 and M5 subtypes (excluding M0-M3 patients). Similar pathways, including the leukocyte
activation signature, were still enriched among M4 and M5 patients.
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Mutation enrichment by TRIM24 mRNA expression:
To

determine

differences

if

Table 2: Enrichment of common mutations based on TRIM24 mRNA expression

in

mutation

patterns

existed

between

TRIM24 high and
low

expressing

groups in TCGA,
we compared the
frequency

of

mutations for the
top

12

most

frequently mutated
genes
between

in

AML
both

groups. Defining high and low TRIM24 expression based on the mean, or based on TRIM24
expression greater or less than 1 standard deviation from the mean both yielded the same
associative patterns between TRIM24 mRNA expression and mutation frequency among the 12
genes (results in table 2).
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TRIM24 mRNA expression in non-AML TCGA datasets:
In order to gather a more

Figure 19: TRIM24 mRNA expression correlates with
survival in human thyoma patients

complete understanding of the biology
behind loss of TRIM24 expression in
AML, we sought to find examples of loss
of TRIM24 correlating with poorer
survival in other human malignancies.
To this end, we analyzed survival based
on TRIM24 expression among all TCGA
datasets possessing mRNA sequencing.
From

the

data

available,

reduced

TRIM24 mRNA expression correlated
with poorer survival in TCGA thyoma
patients. Shown in (figure 19), patients

The y-axis represents percent of surviving patients while the
x-axis represents months of patient survival post-diagnosis.
TRIM24 high expressing patients (red) and TRIM24 low
expressing patients (blue) were separated into their
respective groups based on their TRIM24 expression in
comparison to the mean TRIM24 expression of the group.
All data was obtained from the thyoma dataset in TCGA.

below mean TRIM24 mRNA expression
displayed poorer survival when compared to patients above mean TRIM24 mRNA expression,
with a p-value of 0.0215 when comparing the two groups.
To gather an understanding of the pathways putatively responsible for this survival
relationship, we performed a gene enrichment analysis among TRIM24 co-expressed genes in
TCGA thyoma patients. Similar pathways to those enriched among the AML patients, including
the leukocyte activation signature (p-value 0.00943), were enriched among genes negatively
associated with TRIM24 expression in thyoma patients.
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TRIM24 Expression by Cell Type:

Figure 20: TRIM24 mRNA expression is
decreased in mature hematopoietic cell types.

To first gain an understanding of how
TRIM24 could putatively affect hematopoiesis,
we examined TRIM24 mRNA expression by each
major

cell

type

in

the

hematopoietic

differentiation hierarchy. This was accomplished
by once again utilizing the batch-corrected data
from the BloodSpot database. Demonstrated in
figure 20, TRIM24 mRNA is highest among
HSCs, and decreases with increasing levels of
cell maturation, with (BC, PMN, and MONO)
displaying

the

lowest

levels

of

TRIM24

expression.
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Figure 20 demonstrates that TRIM24 mRNA
expression is highest in hematopoietic stem cells
(HSC) and lowest in differentiated cell types such
as monocyte (Mono) and granulocytes (PMN).
The y-axis demonstrates batch-corrected TRIM24
mRNA expression values, while the x-axis
contains all categories (cell types) examined. All
batch-corrected mRNA exmamined in this figure
was obtained from the BloodSpot database.

In an effort the role Trim24 may play on
major hematopoietic cell populations, we
enumerated

lymphocyte,

neutrophil,

and

monocyte populations by utilizing side-scatter
and

forward-scatter

metrics

from

cytometry experiments (see methods).

Figure 21: No difference in major cell
populations between Trim24 knockout and
Trim24 wildtype tissue.

a)

flow
As

demonstrated in figure 21, in both Trim24
knockout cells from the bone marrow and
spleen, no difference in cell number was
observed.
b)

Both figures 21 a) and 21 b), no difference in
major cell populations were detected between
Trim24 wildtype and knockout groups. In both
figure 21 a) (bone marrow) and figure 21 b)
(spleen) the y-axis represents the percentage of
cells harvested from the tissue examined. In both
figures, the x-axis contains the categories
measured in each experiment, which are Trim24
knockout (Trim24 -/-) and Trim24 wildtype
(Trim24 WT) groups for neutrophil, monocyte,
and lymphocyte measurements. In figure 21 b),
neutrophil and monocyte counts were
unmeasurably low.
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HOXA cluster expression in healthy bone marrow:
As with the leukemic bone marrow,

Figure 22: No difference in HOXA cluster
expression between Trim24 knockout and
Trim24 wildtype healthy bone marrow

we also used HOXA9 and MEIS1 qPCR
primers to gauge levels of HOX cluster
expression.

As shown in figure 22, no

difference in HOX cluster expression was
indicated by our qPCR.

Figure 22 demonstrates no distinguishable
difference in major HOXA cluster genes was
observed between Trim24 knockout and Trim24
wildtype healthy bone marrow. the y-axis
represents mRNA expression normalized to the
control group (Trim24 wildtype), while the x-axis
contains the categories “Control”, “Trim24
knockout (-/-) HOXA9” and “Trim24 knockout (-/) MEIS1.
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Effect of Trim24 knockout on HSCs:
To determine if the HSC populations could
be affected, fluorophore-conjugated antibodies

Figure 23: No difference in LSK number
between Trim24 knockout and Trim24 wildtype
healthy bone marrow.
a)

were used to perform flow cytometry for the
purpose of enumerating a population enriched for
stem and progenitor cells, known as Lin-, Sca1+,
Kit+ (LSK) cells. As shown in figure 23, the bone
marrow of Trim24 knockout mice (both in 12 week
old and 6 month old mice) displayed no difference

b)

in LSK number when compared to wildtype mice
from the same litter.

Figure 23 demonstrates no difference is observed
for hematopoietic stem & progenitor cells (LSK)
in the bone marrow of Trim24 wildtype and
knockout mice. For both figure 23 a) and figure 23
b), the y-axis represents the total number of LSKs
in the tibia and femur bone marrow of mice. The
x-axis contains all categories measured in the
experiment, which include Trim24 wildtype,
Trim24 heterozygous, and Trim24 knockout mice.
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Long-term competitive bone marrow reconstitution:
To

gather

a

more

complete understanding of any

Figure 24: Trim24 knockout bone marrow shows mild reduction
in reconstitution ability.

putative effects Trim24 may
have on normal hematopoiesis,
we next performed a long-term
bone

marrow

(LTBMR) assay.

reconstitution
Examining

hematopoietic populations in
the context of a LTBMR assay
provides not only a temporal
aspect by repeatedly measuring
peripheral blood populations at
regular intervals, but is also

Figure 24 shows a roughly 2/3 difference in the ability of Trim24
knockout (-/-) cells to reconstitute the bone marrow over a span of 18
weeks. The y-axis represents the percentage of CD45.2-positive cells
observed per sample, which represents the reconstitution ability of
each sample (see methods). The x-axis represents weeks postinjection of donor bone marrow following irradiation.

fundamentally different than observing populations in the steady state, as the replicative stress
forced upon small populations to completely reform the bone marrow can cause otherwise
unobservable phenotypes to arise. This assay provides great opportunities for observing biases
towards cell maturation, but is also great for observing differences in self-renew capacity of HSCs.
As shown in figure 24, the LTBMR assay revealed that mice reconstituted with Trim24 knockout
bone marrow displayed 2/3 the ability to reconstitute the bone marrow when compared to
wildtype. An identical ratio was observed when comparing individual cell types. While our
measurements have some level of variability, this ratio did not change over the 18 week span of
the experiment.
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Discussion & Future Directions:
Trim24 knockout AML in vitro:
Colony formation assays are frequently utilized as a method to gauge the stemness and
self-renewal capacity of cell populations. As is shown in figure 4, Trim24 knockout MLL-AF9
AML cells have an increased ability to form colonies in vitro. This phenotype indicates that, in
comparison to wild-type cells, the Trim24 knockout cell population has an increased number of
stem-cell-like cells or an increased potential for self-renewal. As AML is primarily driven by
malignant stem cells, measurements of in vitro self-renewal capacity have marked implications
for predicting a genotype’s effects on survival in an in vivo system. Accordant with the increased
number of colonies, Trim24 knockout leukemic cells also displayed an increased cell number per
passage. To further examine Trim24’s effects on self-renewal and differentiation in AML in vitro,
Giemsa stains were performed on both the wildtype and knockout cells for the purpose of gauging
levels of cell maturation present in each sample. As can be seen in figure 6, Giemsa staining
revealed no detectable difference in blast cell counts between either cell population, nor showed
visually-distinguishable biases for any specific mature hematopoietic cell type. Although the
extent of cell maturation appears to be similar between the two genotypes, this alone is not
contradictory to the colony formation data. Phenotypic differences may lie within the rare
leukemic initiating cell (LIC) population, which may not be readily observable upon broadly
examining cell maturation through Giemsa staining.
Trim24 knockout AML in vivo:
The limitations of in vitro assays led us to conduct similar in vivo assays for the purpose of better
comprehending TRIM24’s potential relevance in AML. To this end, we performed primary
leukemic transplants to assay the effect of Trim24’s presence in AML. As shown in figure 7, no
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significant survival difference was detected between wildtype and knockout groups; however,
differences in survival frequently do not manifest themselves during the primary transplant.
Often, phenotypic differences only evince themselves after serial transplantations, when the AML
test groups are forced rely more heavily on LIC populations for sustained proliferation (86). After
performing and repeating secondary transplants, mice with Trim24 knockout AML displayed a
marked decrease in survival (figure 8).

This significant survival difference exclusive to the

secondary transplant connotes, in parallel with the colony formation data, a disparity in
maintenance of LICs. As with the in-vitro samples, we next measured broad levels of cell
maturation through both Giemsa staining and Hemavet blood counts. In both cases, no detectable
differences were observed between either genotype, further supporting the notion that Trim24’s
effects on AML may lie within the rare LIC population.
As the data available from Trim24 knockout samples is characteristic of what would be
observed from an increased self-renewal phenotype, we next enumerated the cell population
postulated to be responsible - LICs. As can be seen in figure 9, fluorescent antibody labelling and
subsequent flow cytometry revealed that mice with Trim24 knockout AML displayed a 6-fold
increase in LIC number. The quiescent nature of LICs confers a resistance to conventional
therapeutics, which solely target proliferative pathways (34, 87, 88). Coupled with an elevated
potential for self-renewal, LICs are widely accepted to possess the most potent effect on relapse
and long-term survival of any known AML cell population (87, 88).
A paradigm in LIC maintenance for MLL-fusion driven AML is dysregulation of the
HOXA gene cluster, which plays a central role in regulation of hematopoietic self-renewal in both
malignant and healthy tissue. To determine if this mechanism of action could potentially account
for Trim24’s observed phenotypes, we performed qPCR on Trim24 knockout and wildtype
samples to measure the extent to which presence of Trim24 affected expression of the key HOXA
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cluster genes HOXA9 and MEIS1, both of which play roles in AML progression (89).
Interestingly, in both leukemic bone marrow and in vitro samples, differences in the expression
of neither were observed. While not indicative of any particular mechanism, these data suggest
that Trim24’s effect on the LIC population may be independent of HOXA cluster expression.
More profoundly, this may indicate that Trim24’s effects on AML may be largely independent of
MLL-direct targets (including the HOXA cluster); however, further experimentation is required
to explore this possibility. A substantial portion of therapeutic strategies for MLL-fusion AML
operate through targeting these pathways, giving our current results encouraging potential for
original clinical applications. The identification of a pathway novel with respect to AML LIC
maintenance may illuminate previously unappreciated targets of clinical relevance, potentially
opening up options for novel independent or combinatorial therapies.
TRIM24 in AML TCGA data:
Although experimentation in mice is generally an improvement over in vitro assays,
limitations still exist. One such limitation is that merely a small fraction of drugs relevant in mice
move past phase III clinical trials. To increase a study’s probability of maintaining relevance in
human trials, obtaining the maximum amount of available data from human tissue is of paramount
importance.

Accordingly, The Cancer Genome Atlas (TCGA) is a consortium involving

participation from the NCI, NHGRI, and researchers from several hospitals, all aimed at
comprehensively recording high-quality genomic information from human patients across 33
different cancer types.

Along with recording next-gen sequencing data, an abundance of

additional metrics were also recorded, enabling statistical association of mutation and expression
data with patient characteristics. Among the samples available in this database, tissue from 173
adult AML patients had undergone both genomic and RNA sequencing.
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We first used this information to search for associations between TRIM24 expression and
both patient prognosis and mutation status. This inspection revealed that high TRIM24 mRNA
expression correlated with both low risk molecular and cytogenetic markers (figure 11 a).
Furthermore, mutation rate was not correlated with TRIM24 mRNA expression (figure 11 b),
suggesting TRIM24’s association with low risk prognosis markers is not an artifact arising from
a lower mutation rate. Concordantly, a separate database holding a collection of leukemic and
healthy hematopoietic microarray datasets (BloodSpot) demonstrated that TRIM24 expression is
reduced in AML when compared to HSCs (figure 13). This observation reinforces our hypothesis,
as expression differences between HSCs and AML samples frequently represent alterations
beneficial to leukemia. To further investigate TRIM24’s relevance in human AML, we next
obtained mRNA sequencing data from TCGA AML patients, and compared survival between
patients above and below mean TRIM24 expression. As can be seen in figure 14a, patients with
high TRIM24 expression displayed a greatly increased survival, with a mean survival time 1.8
times greater than patients with low TRIM24 expression. With the collaboration of Yi Zhong (a
senior statistical analyst for the department of Epigenetics & Molecular Carcinogenesis at MD
Anderson), we next performed a more thorough survival analysis by removing arbitrary cut-offs
such as “the mean” (see methods) (figure 15). From this analysis, the survival difference remained
strikingly prominent, yielding a p-value of 0.0007. A caveat to this result is our observation that
high TRIM24 expression is strongly associated with the M3 subclass of AML, which indisputably
has the most favorable prognosis. However, after excluding all M3 patients, TRIM24 expression
still substantially correlated with survival (figure 14b), suggesting the observed survival trend is
not merely an artifact of subtype-specific expression patterns. While the number of AML patients
in TCGA is insufficient to perform a comprehensive multivariate analysis, all three survival
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analyses correspond with both our data and original hypothesis that loss of TRIM24 promotes the
progression & aggressiveness of AML.
In line with our murine AML LIC and blast percentage data, metrics recorded by TCGA
also demonstrate that TRIM24 expression does not correlate with peripheral blood blast
percentage, bone marrow blast percentage, platelet count, basophil count, nor white blood cell
count (figure 16). As with the in vitro and in vivo data, the lack of a correlation between TRIM24
expression and visually enumerable cell populations suggests that the survival trend in human
patients could potentially be the result of altered characteristics of the LIC pool. Also in-line with
our in vitro and in vivo data, an examination of co-expression between TRIM24 and HOXA cluster
genes in TCGA revealed no substantial association between the two (figure 17). This is directly
in-line with the hypothesis that TRIM24 is affecting survival through means other than canonical
hematopoietic self-renewal pathways. To further investigate the validity of this theory, we next
examined the co-expression in TCGA between TRIM24 and a leukemic stem cell signature known
for intensely correlating with patient survival, referred to as “Gentles leukemic stem cell up” in
the Gene Ontology (GO) database (90). In congruency with the HOXA cluster expression data,
TRIM24 was not significantly correlated with the leukemic stem cell signature (Table 1). This
result further supports the potentiality that the observed effects are a consequence of aberrations
in a pathway novel with respect to AML progression.
To gather a more complete understanding of the pathways through which Trim24 could
be affecting survival, we utilized co-expression data from TCGA to perform gene-enrichment
analysis, yielding pathways enriched in both the top 1% of genes co-expressed with Trim24, and
separately the top 1% of genes negatively co-expressed with Trim24. While not excluding the
possibility, this analysis did not indicate that loss of Trim24 is negatively affecting human survival
through other common oncogenic pathways. However, the gene enrichment analysis did reveal
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that many immune-related pathways were associated with low TRIM24 expression. While these
immune regulatory pathways have no reported roles in AML, a re-examination of TCGA AML
survival data revealed that one in particular, the leukocyte activation signature, negatively
correlated with patient survival to a statistically significant extent (figure 18). Our collaborator,
Yi Zhong, independently validated the signature’s association with survival through ranked
survival analysis utilizing an optimized cut-off (see methods).
A caveat worth mentioning is the observation that low TRIM24 expression is associated
with the M4 and M5 subclasses of AML (figure 12), both of which exhibit mature leukocytic
features and poor survival. To evaluate this association as a potential artifact explaining the
observed signature and corresponding survival, a separate gene enrichment analysis was
performed exclusively on M4 and M5 patients. Consequently, the analysis revealed that TRIM24
expression still negatively correlated with leukocyte activation, suggesting TRIM24’s association
with the pathway is not merely an artifact of subtype-specific expression patterns.
In an effort to formulate a more complete picture of TRIM24’s participation in human
malignancy, a broad examination of TRIM24 expression among all TCGA data sets revealed that
low TRIM24 expression also correlated with poor survival in thyoma patients. Like the correlation
of TRIM24 expression and survival in AML patients, this observation is also unreported in the
literature. Perhaps more relevant to our hypothesis, however, is the observation that the leukocyte
activation signature was also found to be negatively associated with TRIM24 expression in
thyoma. This observation strongly bolsters the potential biological legitimacy of the statistical
association between TRIM24 and leukocyte activation in AML, as such a highly similar statistical
anomaly occurring in two separate TCGA datasets is unlikely. These data, in combination with
both previous reports of TRIM24 expression associating with favorable bone marrow status in
ALL and our concordant experimental results, strengthen the legitimacy of TRIM24’s statistical
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association with survival in AML. This information altogether suggests that leukocyte activation
may be the non-canonical pathway through which TRIM24 expression exerts its observed effect
on LICs in mice, and could potentially be the underlying reason why TRIM24 expression
correlates with survival in human patients.
The apparent biological connection between TRIM24 and leukocyte activation should be,
perhaps, unsurprising when examined in the context of the known role TRIM family members
play in immunity. A number of TRIM family members have been demonstrated to participate in
the regulation of interferon signaling, repression of retroviral elements, and cytokine transcript
production (58, 59). These relationships provide rationale for TRIM24’s effect on AML LICs,
when examined in the context of the HSC niche. The HSC niche is, in part, regulated by cytokines
produced by surrounding immune cells, such as the production of IL-3 and GM-CSF by T-cells
to support maintenance of HSCs (91-95). Correspondingly, genes comprising the “leukocyte
activation” signature include several cytokines, as well as genes involved in their production and
subsequent secretion. While many aspects of HSC maintenance are disrupted through aberrant
regulation in AML, many of the same components affect the regulation of LICs(94, 96, 97).
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While mechanistic studies are required to provide the information needed formulate a
robust model, our current hypothesis is that TRIM24 is indeed affecting AML leukemogenesis
and progression by manipulating the expression of genes involved in the aforementioned
“Leukocyte Activation” signature. More specifically, we hypothesize that loss of TRIM24
expression alters the cytokine milieu in a cell-autonomous manner to support leukemic
progression. In this hypothetical model (graphically described in figure 25), TRIM24 represses a
multitude of elements involved in immune regulation, including a collection of cytokines. Upon
ablation of TRIM24 expression, these cytokines, which partly comprise the leukocyte activation
Figure 25: Current hypothesis from data available

signature, become overexpressed in AML cells. Consequently, leukemic cells directly disrupt
components of niche maintenance (such as IL-3 and GM-CSF signaling) and enforce positiveregulation of LIC niche characteristics that hinder patient survival. Although existing evidence
is currently at an extremely preliminary stage, this hypothetical model outlines the rationale for
further investigation of the relationship between TRIM24 and leukocyte activation in AML.

41

TRIM24 in normal hematopoiesis:
With evidence suggesting a role for TRIM24 in the regulation of LICs, we postulated that
TRIM24 may too regulate normal hematopoiesis in a similar fashion. While the literature
describes roles for TRIM24 in affecting immune cell expression, no reports to-date demonstrate a
role for TRIM24 in hematopoietic maintenance or maturation. Upon re-examining the BloodSpot
datasets with particular focus on healthy hematopoietic cells, we observed that TRIM24
expression is highest in HSCs and decreases with cell maturation, being lowest in myelocytes and
monocytes.

If TRIM24 indeed negatively regulates leukocyte activation, this decrease in

expression would be expected, so as to allow for the fulfillment of normal immune cell functions
in mature hematopoietic cell types.
Paralleling our leukemic data, Giemsa staining of healthy Trim24 knockout bone marrow
and blood revealed no significant difference in cell maturation levels. Furthermore, a more
intensive analysis of cell maturation was performed by utilizing flow cytometry to enumerate
various hematopoietic lineages in the blood, spleen, and bone marrow, the results of which also
failed to show any distinguishable difference between the two genotypes. Although no differences
in cell number were observed, we sought to also directly enumerate the HSC populations of each
genotype. To this end, long-term and short-term HSC populations were enumerated by once again
performing flow cytometry analysis; however, after several repetitions, the results indicated no
detectable difference between the two genotypes (figure 23). While these results are unsupportive
of the hypothesis, differences in the ability to maintain a self-renewing stem cell population do
not always manifest themselves from merely observing blood or bone marrow cell populations in
the steady-state. The gold standard within this field for simultaneously comparing both selfrenewal capacity and differentiation biases between two genotypes is the long-term competitive
bone marrow reconstitution assay. This assay enables the comparison of each genotype’s ability
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to completely reconstitute the bone marrow and blood of lethally irradiated mice. By utilizing a
variety of flow-cytometry antibodies, the extent to which each hematopoietic lineage is
reconstituted can be individually measured. After recording the ratio of wild-type and Trim24
knockout cell populations in the blood at 2-week intervals for 18 weeks, we sacrificed the mice
and measured hematopoietic cell populations in the spleen and bone marrow. In all cases, the
staining revealed no apparent bias for Trim24 knockout cells to produce any specific cell-type. In
contrast, a 2:3 ratio of total reconstitution ability was observed between Trim24 knockout and
wildtype samples (figure 24); however, while statistically significant, this difference in magnitude
is mild. Repetition of this assay is needed to verify its results, as the observed discrepancy could
merely be an artifact of improper sample preparation or test conditions. In line with this statement,
a separate study reported no reconstitution advantage for Trim24 knockout or wildtype bone
marrow (98). Taken together, these data do not support our hypothesis that TRIM24 plays an
important role in normal hematopoiesis.
Future directions:
Before the commencement of further testing, we need to further optimize our in vivo
protocols. In several attempts to repeat the primary leukemic transplants, Trim24 wildtype
leukemic bone marrow failed to engraft in immune-compromised mice. While the repeated
successful engraftment of Trim24 knockout leukemic bone marrow itself touts support of our
hypothesis for Trim24’s role in leukemic progression, widespread results from the field
demonstrate no issues with the engraftment of control cells. Without the development of leukemia
within the control group, we cannot be certain all aspects of the protocol are being repeatedly
properly. This issue must be addressed to not only provide repeats to enable clear statistical
assessment of our observed data, but also to ensure no unforeseen confounding factors generate
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artifacts within the data. Upon resolving this issue, further in vivo testing, such as additional
survival analyses and measurement of cytokine levels, can progress.
To further evaluate the legitimacy of our gene enrichment analyses from TCGA data, we
aim to use next-generation sequencing methods such as RNA-sequencing (RNA-seq) and
chromatin immunoprecipitation sequencing (ChIP-seq) for the purpose of assessing the
participation of pathways and individual genes through which Trim24 could be exerting its effects
in mice. Unlike the human TCGA data, testing a single sub-type of AML in highly inbred mouse
strains removes the need for complex multivariate analyses. Furthermore, the capability of
performing ChIP-seq in parallel with RNA-seq would enable for the cross-referencing of the
resulting datasets, vastly limiting the potential regulators through which Trim24 directly exerts its
effects.
Beyond TRIM24’s effects on gene expression, the protein’s nuclear receptor interactions
or E3 ubiquitin ligase activity could be responsible for our observed phenotypes. To address these
possibilities, we intend to repeat our in vivo experiments with mice harboring non-synonymous
mutations in the LXXLL motif of Trim24 (responsible for nuclear receptor interactions). This
assay should partly reveal the extent to which TRIM24’s direct interaction with nuclear receptors
effects TRIM24’s observed phenotypes in AML. In order to narrow down which receptor/s may
depend on TRIM24 for nominal signaling in AML, monitoring the output of various nuclear
receptors (with a key focus on retinoic acid receptor) should be experimentally assayed through
qPCR of key targets for each receptor. Expanding on this assay by performing a non-biased
method such as immunoprecipitation followed by mass spectrometry could yield a more complete
understanding about the TRIM24 interactome, further guiding mechanistic investigations of
TRIM24 in AML. Although we do not anticipate TRIM24’s observed tumor suppressive activity
in AML to be the result of P53 ubiquitination & degradation, we do expect that studying
44

TRIM24’s RING domain in AML will provide useful insights into the mechanisms of action of
Trim24 in AML. To this end, the E3 ubiquitin ligase activity of TRIM24 could also be responsible
for many of the aforementioned phenotypes, potentially through targeting proteins other than P53.
For this reason, assessing the effects of catalytically dead TRIM24 in an in vivo AML mouse
model should yield valuable information relevant to the potential mechanisms and intermediary
effectors through which TRIM24 exerts its observed phenotypes.
Recent information from Dr. James Bradner’s group has shed light on potential roles
TRIM24’s E3 ligase activity (RING domain) may play in AML (99). The group utilized a
CRISPR-Scanning strategy to introduce mutations throughout the TRIM24 locus in various acute
leukemic cell lines, and determine which mutations were detrimental to the cell lines’ progression.
The results indicated that the cell lines examined (including the MLL-AF9 expressing AML cell
line, MOLM13) were dependent on an intact TRIM24 RING domain. While this information
may at first appear contrary to the data presented in our study, TRIM24 may play a balancing act
in AML, which could account for the information presented in both studies. Similar to the fine
balancing act TRIM24 plays in hepatocellular carcinoma, overexpression and underexpression of
TRIM24 in AML could both have oncogenic consequences, albeit through different pathways.
The stark difference in survival times between high and low expressing TRIM24 patients may
simply result from the varying molecular paths each group may take to achieve oncogenesis,
potentially by leading to dissimilarities in disease progression or response to treatment.
This rationale leads to predictions for mutation patterns in AML. For example, if a subset
of patients maintain high TRIM24 expression for the oncogenic purpose of down-regulating P53,
fewer TP53 mutations should be observed, as the redundancy of such mutations will not aid the
selection of an evolving malignancy. Conversely, low-expressing TRIM24 patients would be
expected to have a higher frequency of TP53 mutations, as that would rescue the ability to reduce
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P53 function lost with TRIM24 expression. In accordance with this rationale, upon examining
TP53 mutations among TCGA AML patients, we indeed observe this trend, with 11 out of 13
TP53 mutant patients displaying TRIM24 expression below the mean. However, a sample size of
only 13 TP53 mutations is simply too small to give any statistical weight to this observation (pvalue = 0.11). A larger sample size of mRNA expression and patient mutation data would be
required to obtain the number of TP53 mutants requisite for such an analysis. While this
information is lightly supportive of TRIM24 playing a balancing act in AML, a genome-wide
mutation analysis in the context of TRIM24 expression could provide further insight into which
molecular landscapes coordinate with varying levels of TRIM24 expression.
While current data does not support a role for TRIM24 in normal hematopoiesis, a role
may yet exist in a separate hematopoietic context. Given TRIM24 theorized role in leukocyte
activation, examining hematopoiesis within the context of chronic infection may yield differences
in hematopoietic ability between TRIM24 knockout and wildtype cells. Additionally, assaying
the extent of leukocyte activation in TRIM24 knockout and wildtype immune cells may yield
insight into novel aspects of immunology.
Summary / Conclusion:
Overall, the cumulative data collected in this study supports our hypothesis that loss of
TRIM24 promotes the progression & aggressiveness of AML. While our data did not support the
hypothesis that TRIM24 plays an important role in normal hematopoiesis, this result is exciting
when viewed within the context of clinical relevance. The lack of an apparent role for TRIM24
in normal hematopoiesis suggests that AML therapies targeting the involved pathways may result
in fewer negative side effects, potentially enabling a higher dosage and greater anti-leukemic
effect than conventional treatments.

Furthermore, our results lead us to hypothesize that
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TRIM24’s associations with survival are the result of a negative association between the
expression of leukocyte activation and TRIM24. From the available data, we also theorize that
this signature’s correlation with poor prognoses is the result of altered regulation of leukemic
initiating cells. Regardless of the true presence, or lack thereof, of a relationship between
leukocyte activation and TRIM24 expression, studying both in the context of AML progression
will likely be a rewarding endeavor for providing a more comprehensive understanding of
leukemogenesis and development of therapeutics. Ultimately, this study succeeded in providing
a framework for guiding the continued research of TRIM24 in AML.
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Materials & Methods:
Cell culture: Unless otherwise specified, all cells in this study were cultured in RPMI 1640 with
2mm glutamine, cultured at 5% CO2, 37 degrees in Corning Falcon® 10 cm dishes (REF 353003).
All cell counts were performed by first spinning down harvested cells at 1500 RPM for 5 minutes
at 4 degrees, and subsequently resuspending in PBS. 10 ul of this solution was then mixed with
10 ul of AOPI (Acridine orange & propidium iodide) stain and loaded onto a slide. Cells on the
slide where then counted by a Cellometer® K2 machine.
Colony formation: All colony formation assays were performed with StemCell™ Methocult™
M3234 semisolid media (Cat# 03234), supplemented with 5 ng/ul IL-3, 5ng/ul, IL-6, 100 ng/ul
SCF, and pen-strep antibiotic. Cultures were seeded with 5,000 cells in 2 mL Methocult in
Corning Costar® 6-well plate (REF 3506). Plates were left in incubator with 5% CO2 at 37 degrees
for 10 days, at which point all plates were imaged with a Nexcelom Bioscience Celigo®-S to a
resolution of 2 um per pixel. The resulting images were used to count colony types manually.
Storage of Cells: All cells were stored in freezing medium consisting of 90% FBS and 10%
DMSO. Cells were harvested from cultures, washed in PBS, spun down at 1500 RPM for 5
minutes at 4 degrees, and subsequently re-suspended in freezing medium to a density of 4 x 106
cells per milliliter. The resulting suspensions were then aliquoted into Corning 2 mL cryovials
(REF 430488), with 1.5 mL in each vial. The cryo-vials were next placed in a Nalgene cryo
freezing container (Cat# 5100-0001), insulated with isopropanol, and placed in a -80 degree
freezer. After allowing to freeze overnight, all vials were next transferred to boxes stored in liquid
nitrogen.
qPCR: All RNA analyzed was harvested by following the TRIzol® protocol for harvesting RNA
from suspension cells. Subsequently, cDNA copies of RNA were made by following the Bio48

Rad iScript™ Reverse Transcription Supermix protocol for generating cDNA. Per each well in
our qPCRs, reaction mixtures were comprised of 5 ul SYBR Green master mix, 1ul forward
primer, 1ul Reverse primer, 1 ul from 1:10 diluted cDNA stock, and 1 ul of DEPC water. The
working stocks for each primer were 10 uM. All qPCRs were performed on a 7500 Fast RealTime PCR System from Applied Biosystems. The machine was set to expose the sample to 95C
for 5 minutes, then 40 cycles of 95C for 15s, 60C for 30s, and 72C for 30s. One final cycle was
performed of 95C for 15s, 60C for 60s, 95C for 30s (during which melt curves were generated),
and 60C for 15s. GAPDH was used as the reference gene for all qPCR experiments. All primers
can be found in table 3.
Table 3 – primer sequences used in this study

Retroviral infection and bone marrow transformation : BOSC cells, previously frozen in
freezing media, were thawed and allowed to recover for one passage in a Corning Falcon® 10 cm
dish (REF 353003). BOSC cells were recovered and grown in DMEM with 10% FBS and penstrep antibiotic. In the afternoon, 0.4 x 106 cells were plated in each well of a Corning Costar® 6well plate (REF 3506) and allowed to grow overnight to approximately 70% confluence. Per well
of cells, 6 ul of DNA:XtremeGene-9 was mixed with 1.6 ug of MLL-AF9 plasmid, 1 ug of pCL49

Eco plasmid, and 94 ul of Opti-MEM. The reagents were mixed via pipette and allowed to
incubate at room temperature for 15 minutes. 100 ul of the resulting mixture was added to each
well of BOSC cells. 72 hours before transfection, donor mice were injected with 5-fluorouracil
for the purpose of killing proliferating cells, and thus enriching donor bone marrow for
hematopoietic stem and progenitor cells.
24 hours post-transfection, bone marrow from 8 – 12 week old mice was harvested, and plated in
Corning Cellgro® DMEM (REF 10-013-CV) with 4ml per well and 2.5 million cells per well.
5ng / mL IL3, 5ng / mL IL6, and 100ng / mL SCF were added to the media, and cells were allowed
to incubate at 37C for roughly 24 hours, to stimulate cell division.
48 hours post-transfection, BOSC culture supernatant (containing retrovirus) was harvested, and
replaced with 2 mL of fresh DMEM. Viral supernatant was supplemented with the same mixture
of cytokines described above, with the addition of 4ug / mL polybrene. Viral supernatant was
then distributed equally among donor bone marrow cultures, which were subsequently spun at
2500 rpm for 90 minutes at 25C, then placed back in the incubator. 72 hours post-transfection,
the collection and spinning of viral supernatant was repeated. The BOSC cells were harvested
and run through flow cytometry analysis to determine transfection efficiency by measuring the
percentage of GFP positive cells.
96 hours post-transfection, donor bone marrow cells were cultured in Corning Falcon® 10 cm
dishes (REF 353003) with StemCell™ Methocult™ M3234 semisolid media (Cat# 03234),
supplemented with 5 ng/ul IL-3, 5ng/ul, IL-6, 100 ng/ul SCF, and pen-strep antibiotic.
1-week post-transfection, donor bone marrow cells were harvested, spun down at 1500 rpm for 5
minutes at 4C, resuspended in 1mL of PBS, and placed on ice. A small fraction of these cells
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were run through flow-cytometry to determine infection efficiency by measuring the percentage
of GFP positive cells.
Primary leukemic transplant: To carry out primary leukemic transplants, NOD-SCID mice 812 weeks of age were injected through the tail vail with 100,000 GFP+ donor bone marrow cells
from the transformation protocol. Mice were then monitored over the course of 100 days, and
euthanized when displaying moribund leukemic symptoms, such as hunched posture, immobility,
unkempt fur, short & rapid breathing, and closed or winced eyes. Blood, bone marrow, and
spleens were all harvested after sacrificing leukemic mice. A leukemic diagnosis of each mouse
was later confirmed by running bone marrow cells through flow cytometry to determine the
percentage of GFP+ cells.
Secondary leukemic transplant: Secondary transplants were performed by harvesting leukemic
bone marrow from mice which succumbed to leukemia in the primary transplant experiment as
follows: the percentage of leukemic cells in the BM of primary recipients was determined by
measuring the GFP percentage via flow cytometry. Based on this percentage, 100,000 GFP+ cells
were subsequently injected into NOD-SCID mice 8 – 12 weeks of age. Mice were then monitored
over the course of 100 days, and euthanized when displaying moribund leukemic symptoms.
Blood, bone marrow, and spleens were all harvested after sacrificing leukemic mice.
Tail vein injection: Injections were carried out by placing mice in a restrainer specifically
designed for tail vein injection, which holds the body of the mouse in place while exposing the
tail.

The tail was then warmed with a heat pad to induce vasodilation of the tail vein.

Subsequently, a 28 gauge insulin needle was used to inject 200 ul of solution into mice. Such
solutions varied on the experiment being conducted, but included bone marrow, leukemic cells,
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and 5-fluorouracil (5FU). All 5FU injection solutions were prepared by mixing 5mg of 5FU with
PBS for a final volume of 200 ul.
Euthanasia: In line with IACUC standards, mice were euthanized via CO2 exposure in home
enclosures with a flow rate of 30% displacement (1.8 liters) per minute until 1 minute after mice
stop breathing (typically 6 minutes for adult mice). Our lab is approved to employ cervical
dislocation or exsanguination as secondary euthanasia methods. For most mice, the thoracic
cavity was immediately opened and the heart subsequently severed to not only ensure
exsanguination as a secondary euthanasia method, but also to enable for the collection of large
blood samples.
Harvesting of bone marrow: Immediately following euthanasia, mice were sprayed with 70%
EtOH, and skin on the lower half of each animal was removed. Without damaging the ilium, the
hind quarters were severed above the femur and immediately placed in ice-cold PBS. In a sterile
hood, all muscle and ligaments were removed from the bone, and the femur and tibia were
separated. A small incision was made on each end of the bones, and then PBS was flushed through
them with a 28 gauge syringe, collecting all of the flow-through in a 1.5 mL tube. This process
was repeated until visibly all bone marrow had been flushed from the bones. The solution with
bone marrow was then spun at 2000 RPM at 4 degrees for 5 minutes, washed with PBS,
subsequently spun at the same speed and resuspended in the desired volume for immediate usage,
or frozen in freezing medium for future use.
Harvesting of spleen: Immediately following euthanasia, spleens were removed from the same
mice from which bone marrow was harvested. The spleens were removed by extending the
incision in the thoracic cavity (a remnant from the euthanasia protocol) downwards to expose
organs in the abdomen. By gently moving intestines aside with forceps on the animal’s left side,
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the spleen was subsequently removed by using surgical scissors to separate the spleen from
surrounding connective tissue. All spleens were immediately placed in ice cold PBS before future
processing. For experiments in which sectioning of the spleen is intended, we halved the spleen,
storing one half in 10% neutral buffered formalin (pH 6.8 – 7.2). The other half would then be
forced through a 40 micrometer nylon cell strainer to separate the spleen into single cells. These
cells would be washed in PBS, and were used for flow cytometry experiments, with excess cells
being frozen in freezing medium.
Long-term competitive bone marrow reconstitution assay: CD45.1 C57/BL6 mice obtained
from Charles River were committed to be recipients for the bone marrow transplant, and were
thus irradiated with a lethal dose of 950 rads prior to receiving donor bone marrow. These mice
were homozygous for the CD45.1 allele of CD45, so as to make any remnant cells distinguishable
through flow cytometry from our test groups, which were homozygous for the CD45.2 allele.
Donor bone marrow was harvested from Trim24 knockout mice, Trim24 wildtype mice, and
CD45.1 homozygous C57/BL6. Separately, Trim24 knockout and Trim24 wildtype bone marrow
were mixed with bone marrow CD45.1 C57/BL6 mice to obtain a 50:50 ratio of CD45.1 and
CD45.2 cells (1.5 x 106 from each group). Both bone marrow mixtures (Trim24 knockout /
CD45.1 and Trim24 wildtype / CD45.1) were injected into recipient mice, five for each group.
Every 2 weeks for the span of 18 weeks, in each mouse the bone marrow reconstitution ability
was measured by comparing the ability of Trim24 knockout and Trim24 wildtype cells to outcompete CD45.1 wildtype cells. The comparative ability of each genotype to reconstitute the
blood is represented the ratio of CD45.1 and CD45.2 cells in each mouse, as measured by flow
cytometry.
Geimsa stains: 50,000 cells in 50ul were first loaded onto a Thermo Scientific Cytoslide™ (REF
5991056) and subsequently adhered to the slide’s surface through a cytospin protocol (800 rpm
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centrifugation for 5 minutes). The resulting slides were placed in May-Grunwald stain for 7
minutes, then lightly rinsed with water. The slides were next placed in Giemsa stain, diluted 20fold with distilled water, for 20 minutes. The slides were again lightly rinsed with water, and left
face-up on a flat surface to air-dry. Blast percentages were counted by manually examining each
slide under a microscope.
Harvesting Blood Post-mortem: After severing the heart, blood was allowed to pool in the
bottom of the thoracic cavity for approximately 15 seconds. The pooled blood was then collected
with a 1 mL pipet, and immediately transferred to a BD Microtainer® tube containing a K2EDTA
anti-coagulating solution (REF 365974). Each vial was either manually shaken or left on a rocker
before analysis.
Harvesting Blood from Live Mice: All blood from live mice was collected by puncturing the
facial vein with a 4mm lancet. 8 droplets of blood (approximately 100 – 200 ul) were collected
from each mouse, directly in a BD Microtainer® tube containing a K2EDTA anti-coagulating
solution (REF 365974). Each vial was either manually shaken or left on a rocker before analysis.
Blood Counts: Blood collection tubes were placed into the HemaVet® hemacytometer, which
takes 20 ul of blood from the sample and records numbers of leukocytes, neutrophils,
lymphocytes, monocytes, eosinophils, basophils, erythrocytes, and thrombocytes.
Processing of Peripheral Blood: Immediately after harvest, blood samples were brought up to
10x the original volume with gibco® ACK lysis buffer (REF A10492-01). Samples were
incubated with the buffer for 15 minutes at room temperature, periodically rocking the tubes
manually. Each sample was then spun down at 2000 rpm at 4 degrees for 5 minutes, and all
supernatant was removed. Each pellet was then resuspended in an additional 1 mL of ACK lysis
buffer, and incubated for an additional 10 minutes at room temperature. Subsequently, 5 mL of
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PBS was added to each sample and was then spun down at 2000 rpm at 4 degrees for 5 minutes,
and all supernatant was removed.
Flow Cytometry: All flow cytometry was performed at the MD Anderson North Campus Flow
Core. After harvesting or thawing the desired cells and obtaining the desired cell concentration,
all flow samples were incubated in a primary antibody solution (concentrations & combinations
can be seen in table 4) for 1 hour in the dark on ice. Each sample was subsequently spun at 1500
rpm at 4 degrees for 5 minutes. If a secondary antibody was required, it was instead resuspended
in the secondary antibody solution and incubated for 1 hour in the dark on ice, otherwise each
sample was resuspended in 300 ul of PBS with 2% FBS. Each sample was then passed through
a 35 um nylon cell strainer and moved to a Falcon® 5 mL round bottom tube on ice. All samples
and controls were then given to the core and run on a Gallios flow cytometer.
Table 4 – antibody combinations & concentrations
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TCGA data: All TCGA data was downloaded through the cBioPortal, an online website
dedicated to providing access to annotated TCGA results, as well as providing a query function
to download data relevant to only genes of interest. These data included sequencing data from
200 adult AML patients, with 173 of these patients also having mRNA sequencing recorded.
Metrics analyzed in this study include cell-type numbers, patient survival, patient prognosis, and
patient classification, and expression of individual genes.
TRIM24 mRNA association with quantitative patient metrics: For each quantitative (noncategorical) variable recorded by TCGA examined in this study, linear regression analysis was
performed with TRIM24 mRNA expression, providing correlation coefficients and slopes of
regression. The p-values generated represent the statistical significance of the observed slopes
being non-zero.
TRIM24 mRNA survival analysis: TRIM24’s correlation with overall survival in human AML
patients from the TCGA database was calculated by first separating patients into two groups based
on TRIM24 mRNA expression. Patients with TRIM24 mRNA expression above the mean were
defined as TRIM24 high expressing patients, and those expressing below mean expression were
defined as TRIM24 low expressing patients. Next, survival curves were generated for each group,
the differences between which were statistically evaluated by utilizing a Log-rank (Mantel-Cox)
test. The same protocol was utilized when examining TRIM24’s association with survival in all
other TCGA datasets. The same protocol was also followed upon evaluating TRIM24 survival in
the absence of FAB M3 subtype patients (16 excluded in total). The mean TRIM24 mRNA
expression was re-calculated, and the survival between TRIM24 high and low expressing patients
was re-evaluated.
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Our collaborator Yi Zhong performed an independent survival analysis, in which arbitrary cutoffs
(such as mean) were not used. Instead, he utilized an optimized cutoff value, in which a program
repeatedly performed multiple survival analyses to find a cutoff which associates with survival to
the greatest magnitude. The rationale behind this method is to provide a cut-off value which holds
more biological relevance than any arbitrarily-chosen value. This has the potential to provide
more biologically relevant gene enrichment analyses by separating patients based on that same
cut-off value.
TRIM24 mRNA mutation analysis: The top 12 most frequently mutated genes in TCGA AML
patients (as determined by cBioPortal annotation of patient exome sequencing) were examined
for mutation enrichment based on TRIM24 mRNA expression. Mutation count for each gene
among TRIM24 high and low expressing patients were tallied and compared, the numbers from
which were statistically evaluated by utilizing Fisher’s exact test.
TRIM24 mRNA association with cytogenetic risk: TRIM24’s association with cytogenetic risk
was evaluated by plotting TRIM24 mRNA expression for all patients within the 3 TCGAannotated cytogenetic risk groups, “Good”, “Intermediate”, and “Poor”.

The resulting

information was analyzed statistically by performing a 1-way ANNOVA with Tukey’s multiple
comparison test. The multiple comparison test compared the mean of each group, to the mean of
each remaining group individually, providing an adjusted p-value for the difference obtained in
each comparison.
TRIM24 by French-American-British (FAB) classification of AML: The association of
TRIM24 mRNA with AML FAB subtypes was examined by comparing the mean TRIM24 mRNA
expression of each group, and subsequently performing a 1-way ANNOVA with Tukey’s multiple
comparison test. The multiple comparison test compared the mean of each group, to the mean of
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each remaining group individually, providing an adjusted p-value for the difference obtained in
each comparison.
Gene enrichment analysis: Preliminary gene enrichment analyses were performed by obtaining
TRIM24 co-expression data for the entire genome, provided by cBioPortal. From the genomic
co-expression data, we formulated a list of the top 1% of genes in the genome co-expressed with
TRIM24 mRNA, and a separate list of the top 1% of genes negatively co-expressed with TRIM24
mRNA.

These lists were then separately run through online PANTHER software, which

compares the number of genes in each GO-annotated pathway in your list, and evaluates the
statistical difference of this number with the expected number of genes (under the assumption of
random distribution). The PANTHER software was chosen both for its ease of access, and recent
update of GO pathways (updated monthly). For all results, this protocol was performed unless
otherwise specified.
Our collaborator, Yi Zhong, independently performed a more intensive gene enrichment analysis.
This involved utilizing an algorithm which provides a gene enrichment score for each GO
pathway for each patient. Next, a simply t-test was performed to determine if these gene
enrichment values varied significantly between TRIM24 high and low groups, defined by the same
cut-off obtained in Yi Zhong’s survival analysis.
TRIM24 mRNA in normal hematopoietic cell types: TRIM24’s association with specific
hematopoietic cell types was evaluated by statistically analyzing the relationship between
TRIM24 mRNA expression and corresponding cell type category. These information were
obtained through a database known as BloodSpot, which compiles microarray data from multiple
studies, and uses an algorithm to provide batch corrections to all data, to make the data comparable
between all studies in the database. The statistical relationship between TRIM24 mRNA and cell
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type was computed by performing a 1-way ANNOVA with Tukey’s multiple comparison test.
The multiple comparison test compared the mean of each group, to the mean of each remaining
group individually, providing an adjusted p-value for the difference obtained in each comparison.
TRIM24 mRNA in AML and HSCs: Differences in TRIM24 expression between 5 different
AML subtypes and normal hematopoietic stem cells (HSCs) were statistically evaluated by
performing a 1-way ANNOVA with Tukey’s multiple comparison test on the TRIM24 microarray
data from each group. The multiple comparison test compared the mean of each group, to the
mean of each remaining group individually, providing an adjusted p-value for the difference
obtained in each comparison. The microarray mRNA data was obtained through a database
known as BloodSpot, which compiles microarray data from multiple studies, and uses an
algorithm to provide batch corrections to all data, to make the data comparable between all studies
in the database.
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